Decreased cardiac mortality with nicorandil in patients with ischemic heart failure


Cite item

Full Text

Abstract

Background. Effective treatments in heart failure (HF) patients with ischemic etiology have not been fully established. Nicorandil, combination of nitrate component and sarcolemmal adenosine triphosphate-sensitive potassium channel opener, is a potent vasodilator of coronary and peripheral vessels and has been used as an antianginal agent. Therefore, we examined impacts of nicorandil on cardiac mortality in ischemic HF patients. Methods. Consecutive 334 HF patients with ischemic etiology were retrospectively registered and divided into 2 groups based on oral administration of nicorandil: nicorandil group (n=116) and non-nicorandil group (n=218). We retrospectively examined cardiac mortality. Results: In the Kaplan-Meier analysis (mean follow-up period 963 days), cardiac mortality was significantly lower in the nicorandil group than in the non-nicorandil group (11.2% vs 19.7%, р=0.032). In the Cox proportional hazard analysis, usage of nicorandil was a suppressor of cardiac mortality (hazard ratio 0.512, 95% confidence interval 0.275-0.953, р=0.035), and this result was consistent in several subgroup analyses, such as left ventricular ejection fraction, percutaneous coronary intervention, coronary artery bypass graft, diabetes, р-blockers, and statins. Conclusion. Nicorandil is potentially effective for reducing mortality in patients with ischemic HF Trial registration. This was a retrospective study

About the authors

A. Yoshihisa

Fukushima Medical University

Email: yoshihis@fmu.ac.jp
Department of Cardiovascular Medicine 1 Hikarigaoka, Fukushima 960-1295, Japan

Y. Sato

Fukushima Medical University

Department of Cardiovascular Medicine 1 Hikarigaoka, Fukushima 960-1295, Japan

S. Watanabe

Fukushima Medical University

Department of Cardiovascular Medicine 1 Hikarigaoka, Fukushima 960-1295, Japan

T. Yokokawa

Fukushima Medical University

Department of Cardiovascular Medicine 1 Hikarigaoka, Fukushima 960-1295, Japan

T. Sato

Fukushima Medical University

Department of Cardiovascular Medicine 1 Hikarigaoka, Fukushima 960-1295, Japan

S. Suzuki

Fukushima Medical University

Department of Cardiovascular Medicine 1 Hikarigaoka, Fukushima 960-1295, Japan

M. Oikawa

Fukushima Medical University

Department of Cardiovascular Medicine 1 Hikarigaoka, Fukushima 960-1295, Japan

A. Kobayashi

Fukushima Medical University

Department of Cardiovascular Medicine 1 Hikarigaoka, Fukushima 960-1295, Japan

Y. Takeishi

Fukushima Medical University

Department of Cardiovascular Medicine 1 Hikarigaoka, Fukushima 960-1295, Japan

References

  1. Ponikowski P, Voors A.A, Anker S.D et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37 (27): 2129-200.
  2. Yancy C.W, Jessup M, Bozkurt B et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2013; 62 (16): e147-239.
  3. Fonarow G.C, Albert N.M, Curtis A.B. et al. Incremental reduction in risk of death associated with use of guidelinerecommended therapies in patients with heart failure: a nested case- control analysis of IMPROVE HF. J Am Heart Assoc 2012; 1 (1): 16-26.
  4. Khatibzadeh S, Farzadfar F, Oliver J et al. Worldwide risk factors for heart failure: a systematic review and pooled analysis. Int J Cardiol 2013; 168 (2): 1186-94.
  5. Felker G.M, Shaw L.K, O'Connor C.M. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 2002; 39 (2): 210-8.
  6. Smith P.K, Puskas J.D, Ascheim D.D et al. Surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med 2014; 371 (23): 2178-88.
  7. Mohr F.W, Morice M.C, Kappetein A.P. et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013; 381 (9867): 629-38.
  8. Deja M.A, Grayburn P.A, Sun B et al. Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. Circulation 2012; 125 (21): 2639-48.
  9. Velazquez E.J, Lee K.L, Deja M.A. et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011; 364 (17): 1607-16.
  10. Petrie M.C, Jhund P.S, She L. et al. Ten-year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction: an analysis of the extended follow-up of the STICH trial (Surgical Treatment for Ischemic Heart Failure). Circulation 2016; 134 (18): 1314-24.
  11. Luo B, W.u P, Bu T. et al. All-cause mortality and cardiovascular events with nicorandil in patients with IHD: systematic review and metaanalysis of the literature. Int J Cardiol 2014; 176 (3): 661-9.
  12. McKee P.A, Castelli W.P, McNamara P.M, Kannel W.B. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285 (26): 1441-6.
  13. Zhao F, Chaugai S, Chen P et al. Effect of nicorandil in patients with heart failure: a systematic review and meta-analysis. Cardiovasc Ther 2014; 32 (6): 283-96.
  14. Kasama S, Toyama T, Iwasaki T et al. Effects of oral nicorandil therapy on sympathetic nerve activity and cardiac events in patients with chronic heart failure: subanalysis of our previous report using propensity score matching. Eur J Nucl Med Mol Imaging 2014; 41 (1): 144-54.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).